ABBOTT PARK, Ill., March 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure. The five-year results from the landmark COAPT™ trial show MitraClip is safe and effective and can cut the rate of hospitalizations while improving survival for heart failure patients with severe secondary (or functional) MR, a condition which has historically been extremely challenging to treat.Read more at prnewswire.com
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.